

# Anteris Technologies Ltd

20:00 14 Mar 2017

## Admedus rewards Paterson with CEO appointment

Admedus (ASX:AHZ) has appointed Wayne Paterson as chief executive officer (CEO) for a three year term commencing immediately.

Paterson has been acting CEO for Admedus since May 2016. During this period, he has overseen a major restructure involving a substantial reduction in costs with significant increases in both revenue and profitability.

The board has unanimously determined that it is in the best interests of the Company that Paterson continues to lead the business and execute his three-year 'Vision 20/20' strategy.

John Seaberg, chairman, commented: "As we saw with his 'Code Red' restructure, Wayne is a strong leader who has the ability, energy, savvy and networks that Admedus needs to accelerate the momentum we've already been able to achieve during just a few months on his watch.

"He is a truly global executive with a track record of delivering above market performance across the world for two decades in the pharmaceutical/health care industry."

### Wayne Paterson

Paterson has held numerous, senior positions in multi-national pharmaceutical companies and has lived in seven countries during the past 25 years.

Throughout his career, he has been responsible for building and managing businesses throughout the world, including mergers, integrations, acquisitions and major restructures as president and CEO.

From 2005 to 2013, he held senior positions at Merck KGaA (ETR:MRK).

In his most recent role as president of Europe, Canada and Australia, he managed over \$3 billion in sales with an operational budget of \$500 million and was a member of the global executive board.

### Background

Admedus holds assets from research and development, through clinical development as well as sales, marketing and distribution.

Its flagship product is CardioCel, which is becoming a surgeon-preferred biomaterial for heart valve repair surgeries.

CardioCel represents a disruptive technology in the \$2.5 billion heart valve repair and replacement market, which is dominated by products commercialized by large medical device companies.

**Price:** 3.75

**Market Cap:** \$22.16 m

### 1 Year Share Price Graph



### Share Information

**Code:** AVR

**Listing:** ASX

52 week	High	Low
	7.5	3.03

**Sector:** Pharma & Biotech

**Website:** anteristech.com

### Company Synopsis:

*Anteris Technologies Ltd (ASX:AVR) is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients.*

action@proactiveinvestors.com

It is now being sold in Canada, Australia, Asia, the Middle East, and North Africa, covering 135 medical centres.

Admedus also recently received FDA 510(k) clearance to market its vascular product, VascuCel in the U.S.

Furthermore, the Admedus infusion portfolio has over 800 customers providing hospital-wide infusion solutions across the Australian and New Zealand healthcare systems.

Beyond CardioCel and infusion sales, Admedus is developing a DNA-based therapeutic vaccine for HSV-2 and HPV.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).